Operating Income (Loss) in USD of OCULAR THERAPEUTIX, INC from 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Ocular Therapeutix, Inc quarterly/annual Operating Income (Loss) history and change rate from 2012 to Q3 2025.
  • Ocular Therapeutix, Inc Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$68.7M, a 49.4% decline year-over-year.
  • Ocular Therapeutix, Inc Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$251M, a 77.6% decline year-over-year.
  • Ocular Therapeutix, Inc annual Operating Income (Loss) for 2024 was -$172M, a 109% decline from 2023.
  • Ocular Therapeutix, Inc annual Operating Income (Loss) for 2023 was -$82.4M, a 4.74% decline from 2022.
  • Ocular Therapeutix, Inc annual Operating Income (Loss) for 2022 was -$78.7M, a 0.79% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

OCULAR THERAPEUTIX, INC Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$251M -$68.7M -$22.7M -49.4% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025
Q2 2025 -$228M -$67.6M -$24.1M -55.2% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025
Q1 2025 -$204M -$63.9M -$32.3M -102% 01 Jan 2025 31 Mar 2025 10-Q 05 May 2025
Q4 2024 -$172M -$50.6M -$30.5M -152% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025
Q3 2024 -$141M -$46M -$26.8M -139% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025
Q2 2024 -$114M -$43.6M -$23M -112% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025
Q1 2024 -$91.5M -$31.6M -$9.07M -40.2% 01 Jan 2024 31 Mar 2024 10-Q 05 May 2025
Q4 2023 -$82.4M -$20M -$688K -3.55% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025
Q3 2023 -$81.7M -$19.2M +$2.33M +10.8% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 -$84M -$20.6M -$654K -3.28% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024
Q1 2023 -$83.4M -$22.5M -$4.72M -26.4% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024
Q4 2022 -$78.7M -$19.4M -$1.31M -7.27% 01 Oct 2022 31 Dec 2022 10-K 03 Mar 2025
Q3 2022 -$77.3M -$21.5M -$2.02M -10.3% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023
Q2 2022 -$75.3M -$19.9M +$315K +1.56% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023
Q1 2022 -$75.6M -$17.8M +$2.4M +11.8% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023
Q4 2021 -$78M -$18M -$3.71M -25.8% 01 Oct 2021 31 Dec 2021 10-K 11 Mar 2024
Q3 2021 -$74.3M -$19.5M -$5.52M -39.4% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 -$68.8M -$20.2M -$2.35M -13.1% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022
Q1 2021 -$66.5M -$20.2M -$3.61M -21.8% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022
Q4 2020 -$62.8M -$14.3M +$7.06M +33% 01 Oct 2020 31 Dec 2020 10-K 06 Mar 2023
Q3 2020 -$69.9M -$14M +$9.14M +39.5% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021
Q2 2020 -$79M -$17.9M +$3.72M +17.2% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021
Q1 2020 -$82.8M -$16.6M +$3.04M +15.5% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021
Q4 2019 -$85.8M -$21.4M -$4.12M -23.8% 01 Oct 2019 31 Dec 2019 10-K 12 Mar 2020
Q3 2019 -$81.7M -$23.1M -$8.33M -56.2% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 -$73.4M -$21.6M -$8.04M -59.2% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020
Q1 2019 -$65.3M -$19.7M -$6.2M -46.1% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020
Q4 2018 -$59.1M -$17.3M -$4.57M -35.9% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020
Q3 2018 -$54.6M -$14.8M +$380K +2.5% 01 Jul 2018 30 Sep 2018 10-K 12 Mar 2020
Q2 2018 -$54.9M -$13.6M +$4.78M +26% 01 Apr 2018 30 Jun 2018 10-K 12 Mar 2020
Q1 2018 -$59.7M -$13.5M +$2.22M +14.1% 01 Jan 2018 31 Mar 2018 10-K 12 Mar 2020
Q4 2017 -$61.9M -$12.7M -$244K -1.96% 01 Oct 2017 31 Dec 2017 10-K 07 Mar 2019
Q3 2017 -$61.7M -$15.2M -$5.96M -64.5% 01 Jul 2017 30 Sep 2017 10-K 07 Mar 2019
Q2 2017 -$55.7M -$18.3M -$7.23M -65.1% 01 Apr 2017 30 Jun 2017 10-K 07 Mar 2019
Q1 2017 -$48.5M -$15.7M -$5.16M -49.1% 01 Jan 2017 31 Mar 2017 10-K 07 Mar 2019
Q4 2016 -$43.3M -$12.5M -$2.2M -21.4% 01 Oct 2016 31 Dec 2016 10-K 08 Mar 2018
Q3 2016 -$41.1M -$9.24M +$1.94M +17.3% 01 Jul 2016 30 Sep 2016 10-K 08 Mar 2018
Q2 2016 -$43.1M -$11.1M -$1.47M -15.3% 01 Apr 2016 30 Jun 2016 10-K 08 Mar 2018
Q1 2016 -$41.6M -$10.5M -$3.4M -47.7% 01 Jan 2016 31 Mar 2016 10-K 08 Mar 2018
Q4 2015 -$38.2M -$10.3M -$2.73M -36.1% 01 Oct 2015 31 Dec 2015 10-K 10 Mar 2017
Q3 2015 -$35.5M -$11.2M -$4.4M -64.9% 01 Jul 2015 30 Sep 2015 10-K 10 Mar 2017
Q2 2015 -$31.1M -$9.64M -$3.69M -62% 01 Apr 2015 30 Jun 2015 10-K 10 Mar 2017
Q1 2015 -$27.4M -$7.11M -$288K -4.22% 01 Jan 2015 31 Mar 2015 10-K 10 Mar 2017
Q4 2014 -$27.1M -$7.55M -$4.13M -121% 01 Oct 2014 31 Dec 2014 10-K 10 Mar 2016
Q3 2014 -$23M -$6.78M -$3.34M -97.3% 01 Jul 2014 30 Sep 2014 10-K 10 Mar 2016
Q2 2014 -$19.6M -$5.95M -$2.96M -98.9% 01 Apr 2014 30 Jun 2014 10-K 10 Mar 2016
Q1 2014 -$16.7M -$6.83M -$3.77M -123% 01 Jan 2014 31 Mar 2014 10-K 10 Mar 2016
Q4 2013 -$12.9M -$3.42M 01 Oct 2013 31 Dec 2013 10-K 20 Mar 2015
Q3 2013 -$3.44M 01 Jul 2013 30 Sep 2013 10-K 20 Mar 2015
Q2 2013 -$2.99M 01 Apr 2013 30 Jun 2013 10-K 20 Mar 2015
Q1 2013 -$3.06M 01 Jan 2013 31 Mar 2013 10-K 20 Mar 2015

OCULAR THERAPEUTIX, INC Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$172M -$89.4M -109% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025
2023 -$82.4M -$3.73M -4.74% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025
2022 -$78.7M -$617K -0.79% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025
2021 -$78M -$15.2M -24.2% 01 Jan 2021 31 Dec 2021 10-K 11 Mar 2024
2020 -$62.8M +$23M +26.8% 01 Jan 2020 31 Dec 2020 10-K 06 Mar 2023
2019 -$85.8M -$26.7M -45.1% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022
2018 -$59.1M +$2.81M +4.53% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020
2017 -$61.9M -$18.6M -42.9% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2020
2016 -$43.3M -$5.13M -13.4% 01 Jan 2016 31 Dec 2016 10-K 07 Mar 2019
2015 -$38.2M -$11.1M -41% 01 Jan 2015 31 Dec 2015 10-K 08 Mar 2018
2014 -$27.1M -$14.2M -110% 01 Jan 2014 31 Dec 2014 10-K 10 Mar 2017
2013 -$12.9M +$768K +5.62% 01 Jan 2013 31 Dec 2013 10-K 10 Mar 2016
2012 -$13.7M 01 Jan 2012 31 Dec 2012 10-K 20 Mar 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.